Our findings suggest that GRK5-IN-2 attenuates hepatic steatosis by suppressing triglyceride synthesis and promoting mitochondrial fatty acid oxidation, potentially through inhibition of GRK2 alongside GRK5. Here, GRK5 is linked to fatty liver disease.